AMGN · Earnings call · 2026Q3T · Full report
Biosimilar Market Competition
AMGEN INC · 2026-11-03 · Importance 59 · Surprise 48 · No source text
Amgen's biosimilar portfolio grew 26% year-over-year to $977 million in quarterly sales. PAVBLU, its EYLEA biosimilar, grew 41% to $300 million, with retina specialists recognizing its prefilled-syringe presentation and Amgen's biosimilar manufacturing and supply capabilities. The company described late-stage candidates for EYLEA HD, OPDIVO, KEYTRUDA, and OCREVUS as opportunities in large markets.
Key facts
- PAVBLU sales increased 41% year-over-year to $300 million in Q3 2026.
- Amgen's biosimilar portfolio grew 26% year-over-year and generated $977 million in Q3 2026 sales.
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | +2.0% | Amgen's biosimilar portfolio grew 26% year-over-year and generated $977 million in Q3 2026 sales. |